Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response

[1]  H. Seow,et al.  Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. , 2008, Oncology reports.

[2]  T. Mok,et al.  A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein–Barr virus DNA as a biomarker of efficacy , 2008, Cancer Chemotherapy and Pharmacology.

[3]  Daniel Birnbaum,et al.  Integrated profiling of basal and luminal breast cancers. , 2007, Cancer research.

[4]  E. Ricevuto,et al.  Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells. , 2007, Oncology reports.

[5]  J. Brunet,et al.  An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). , 2007, International journal of molecular medicine.

[6]  Q. Tao,et al.  Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments , 2007, Expert Reviews in Molecular Medicine.

[7]  J. Grandis,et al.  Antiproliferative Mechanisms of a Transcription Factor Decoy Targeting Signal Transducer and Activator of Transcription (STAT) 3: The Role of STAT1 , 2007, Molecular Pharmacology.

[8]  J. Califano,et al.  The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation , 2007, Oncogene.

[9]  M. Pino,et al.  Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines. , 2006, Cancer research.

[10]  T. Shibata,et al.  Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  J. Whang‐Peng,et al.  Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Y. Bang,et al.  Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa®, ZD1839) in chemotherapy‐resistant non‐small cell lung cancer , 2005, International journal of cancer.

[13]  T. Poon,et al.  Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells. , 2005, In vivo.

[14]  Yusuke Nakamura,et al.  Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839). , 2004, Human molecular genetics.

[15]  D. Schuppan,et al.  Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. , 2004, Journal of hepatology.

[16]  F. Cappuzzo,et al.  Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. , 2004, Journal of the National Cancer Institute.

[17]  E. Baldi,et al.  EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen‐sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR) , 2004, International journal of cancer.

[18]  M. Gulley,et al.  Differential Signaling Pathways Are Activated in the Epstein-Barr Virus-Associated Malignancies Nasopharyngeal Carcinoma and Hodgkin Lymphoma , 2004, Cancer Research.

[19]  W. Mckenna,et al.  Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. , 2003, Cancer research.

[20]  A. Hui,et al.  Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. , 2002, International journal of oncology.

[21]  K. Makino,et al.  Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.